This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vanhove, G. F. Articles by Blaschke, T. F. Search for Related Content PubMed PubMed Citation Articles by Vanhove, G. F. Articles by Blaschke, T. F.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., 11 1997, 2433-2438, Vol 41, No. 11
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

GF Vanhove, JM Gries, D Verotta, LB Sheiner, R Coombs, AC Collier and TF Blaschke
Division of Clinical Pharmacology, Stanford University, California, USA.

The relationship of CD4+ cell response, level of RNA in plasma, and quantitative peripheral blood mononuclear cell (PBMC) titer to apparent drug exposure was investigated by using data from AIDS Clinical Trial Group protocol 229, a multicenter randomized study. Patients received either saquinavir, zalcitabine, or a combination of both, along with open-label zidovudine. Approximately 100 patients were enrolled in each arm, and the primary study duration was 24 weeks. Individual drug exposure, the area under the concentration-time curve, was estimated by using population-based pharmacokinetic methods. Response was defined as the maximum increase in CD4+ cell count or the maximum decrease in RNA in plasma or PBMC titer adjusted for baseline CD4+ cell count, RNA in plasma, and PBMC titer, respectively. Regression of responses on exposure demonstrated an exposure effect for saquinavir which was significant for the maximum increase in CD4+ cell count and the decrease in RNA in plasma. For the PBMC titer, no significant relationship could be demonstrated but the results suggested a trend similar to that of the other response variables. For all three response variables, the slope of the saquinavir exposure response was greater with the triple combination (saquinavir, zidovudine, and zalcitabine) than with the combination of saquinavir and zidovudine, suggesting possible synergism between saquinavir and zalcitabine.

This article has been cited by other articles:

• Marin-Niebla, A., Lopez-Cortes, L. F., Ruiz-Valderas, R., Viciana, P., Mata, R., Gutierrez, A., Pascual, R., Rodriguez, M. (2007). Clinical and Pharmacokinetic Data Support Once-Daily Low-Dose Boosted Saquinavir (1,200 Milligrams Saquinavir with 100 Milligrams Ritonavir) in Treatment-Naive or Limited Protease Inhibitor-Experienced Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 51: 2035-2042 [Abstract] [Full Text]  
• Hickman, D., Vasavanonda, S., Nequist, G., Colletti, L., Kati, W. M., Bertz, R., Hsu, A., Kempf, D. J. (2004). Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir. Antimicrob. Agents Chemother. 48: 2911-2917 [Abstract] [Full Text]  
• Hammer, S. M., Vaida, F., Bennett, K. K., Holohan, M. K., Sheiner, L., Eron, J. J., Wheat, L. J., Mitsuyasu, R. T., Gulick, R. M., Valentine, F. T., Aberg, J. A., Rogers, M. D., Karol, C. N., Saah, A. J., Lewis, R. H., Bessen, L. J., Brosgart, C., DeGruttola, V., Mellors, J. W., for the AIDS Clinical Trials Group 398 Study Team, (2002). Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial. JAMA 288: 169-180 [Abstract] [Full Text]  
• Kakuda, T. N., Page, L. M., Anderson, P. L., Henry, K., Schacker, T. W., Rhame, F. S., Acosta, E. P., Brundage, R. C., Fletcher, C. V. (2001). Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. Antimicrob. Agents Chemother. 45: 236-242 [Abstract] [Full Text]